<div id="readability-page-1"><p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) shares were up 2.5% during mid-day trading on Thursday . The stock traded as high as $15.44 and last traded at $15.35. Approximately 158,013 shares were traded  during mid-day trading, a decline of 22% from the average daily volume of 202,695 shares. The stock had previously closed at $14.98.</p><div><p><span></span><span>Get <strong>Aardvark Therapeutics</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts recently weighed in on AARD shares. Oppenheimer began coverage on shares of Aardvark Therapeutics in a research report on Tuesday, December 23rd. They set an &#34;outperform&#34; rating and a $35.00 price target for the company. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Aardvark Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada reduced their price objective on Aardvark Therapeutics from $19.00 to $18.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, November 14th. Cantor Fitzgerald  reissued an &#34;overweight&#34; rating on shares of Aardvark Therapeutics in a research report on Friday, November 14th. Finally, William Blair began coverage on shares of Aardvark Therapeutics in a research note on Friday, December 12th. They set an &#34;outperform&#34; rating on the stock. One equities research analyst  has rated the stock with a Strong Buy rating, ten have assigned  a Buy rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $32.70.</p><p><b>View Our Latest Research Report on AARD</b></p><h2>Aardvark Therapeutics Stock Performance</h2><p>The stock has a market cap of $334.17 million and a PE ratio of -7.24. The company's 50-day moving average price is $12.49 and its 200 day moving average price is $12.06. </p><p>Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.07. </p><h2>Insider Transactions at Aardvark Therapeutics</h2><p>In related news, CFO Nelson Sun purchased 3,000 shares of Aardvark Therapeutics stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $14.40 per share, for a total transaction of $43,200.00. Following the completion of the transaction, the chief financial officer directly owned 108,484 shares in the company, valued at $1,562,169.60. This represents a 2.84% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Tien-Li Lee acquired 7,000 shares of the business's stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $14.48 per share, with a total value of $101,360.00. Following the completion of the purchase, the chief executive officer owned 1,551,613 shares in the company, valued at $22,467,356.24. This trade represents a 0.45% increase in their position. The disclosure for this purchase is available in the SEC filing. </p><h2>Institutional Trading of Aardvark Therapeutics</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC purchased a new position in shares of  Aardvark Therapeutics during the 3rd quarter valued at $4,248,000.  Cresset Asset Management LLC bought a new stake in  Aardvark Therapeutics during the third quarter valued at about $1,951,000.  Vanguard Group Inc. raised its holdings in  Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company's stock valued at $7,386,000 after acquiring an additional 94,744 shares during the period.  Geode Capital Management LLC lifted its position in shares of  Aardvark Therapeutics by 129.7% in the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company's stock valued at $1,851,000 after acquiring an additional 77,327 shares in the last quarter.  Finally, Citadel Advisors LLC boosted its stake in shares of  Aardvark Therapeutics by 5.9% in the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company's stock worth $18,073,000 after acquiring an additional 76,151 shares during the period. </p><h2>About Aardvark Therapeutics</h2> (Get Free Report)<p>Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.  </p><p>The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Aardvark Therapeutics</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>Virtually Unknown AI Company Solving Trillion-Dollar Problem</li><li>Do not delete, read immediately</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Aardvark Therapeutics Right Now?</h2><p>Before you consider Aardvark Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.</p><p>While Aardvark Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AARD

<p>Aardvark Therapeutics (NASDAQ:AARD) shares rose 2.5% to $15.35 during mid-day trading, with a trading volume decline of 22% from the average. Analysts have mixed ratings, with Oppenheimer setting a price target of $35.00 and Weiss Ratings maintaining a 'sell' rating. The stock has a market cap of $334.17 million and a PE ratio of -7.24. Recent insider purchases include CFO Nelson Sun and CEO Tien-Li Lee. Institutional investors have also increased their stakes in the company, which focuses on developing treatments for autoimmune diseases.</p>

Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher - Time to Buy?